Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM.
EDOXABAN vs HEPARIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin sodium potentiates the activity of antithrombin III, thereby inactivating thrombin and factor Xa, leading to inhibition of coagulation.
60 mg orally once daily
Intravenous: Initial bolus of 80 units/kg, then continuous infusion at 18 units/kg/h. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
The terminal elimination half-life of heparin is dose-dependent: approximately 30 minutes (low dose, e.g., 25 U/kg), 60 minutes (medium dose, 100 U/kg), and 150 minutes (high dose, 400 U/kg). Half-life increases with dose due to saturation of clearance mechanisms.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Heparin is cleared primarily via the reticuloendothelial system and liver, with minimal renal excretion. Unchanged heparin is not significantly excreted in urine. Biliary/fecal elimination is negligible.
Category C
Category A/B
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."